Cost effective analysis of ribosome-component immune modulation

Allergy and Asthma Proceedings

Volumn 30, Issue 4 SUPPL. 1, 2009, Pages

  Fiocchi, Alessandro ^a   Olivieri, Dario ^b   Marcassa, Sergio ^c   Zava, D ^d   Robberto, Elisa ^c  

^a Melloni Hospital   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c Medical Marketing Department   (Italy)

^d Istituto Lusofarmaco d'Italia   (Italy)

Author keywords

Costs; Economic parameters; Immunomodulation treatment; Otitis media; Pharmacoeconomics; Respiratory infections; Rhinopharyngitis; Ribosome component immune modulator (RCIM); Risk reduction; Saving

Indexed keywords

IMMUNOMODULATING AGENT; RIBOSOME COMPONENT IMMUNE MODULATOR; UNCLASSIFIED DRUG;

BRONCHITIS; CHRONIC DISEASE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEALTH SERVICE; HOSPITALIZATION; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; MEDICAL EXAMINATION; OTITIS MEDIA; PHYSICIAN; PRIMARY MEDICAL CARE; PRODUCTIVITY; RECURRENT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; RHINOPHARYNGITIS; SINUSITIS; TREATMENT DURATION;

ANTIGENS, BACTERIAL; COST OF ILLNESS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; IMMUNOLOGIC FACTORS; RECURRENCE; RESPIRATORY TRACT INFECTIONS;

EID: 68949132571     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2009.30.3246     Document Type: Review

References (14)

1. Nsouli TM, Nsouli SM, Linde RE, et al. Role of food allergy in serous otitis media. Ann Allergy Asthma Immunol 73:215-219, 1994. (Pubitemid 24288439)
2. Teele DW, Lundgren K, Casselbrant ML, et al. Recent advance in otitis media. Epidemiology and natural history. Ann Otol Rhinol Laryngol Suppl 139:11-13, 1989.
3. Harabuchi Y, Faden H, Yamanaka N, et al. Human milk secretory IgA antibody to nontypeable Haemophilus Influenzae: Possible protective effects against nasopharyngeal colonization. J Pediatr 124:193-198, 1994. (Pubitemid 24057782)
4. McCutcheon H, and Fitzgerald M. The public health problem of acute respiratory illness in children. J Clin Nurs 10:305-310, 2001. (Pubitemid 33754754)
5. Wald ER, Guerra N, and Byers C. Upper respiratory tract infections in young children: Duration of and frequency of complications. Pediatrics 87:129-133, 1991.
6. Howel D, Webster S, Hayes J, et al. The impact of recurrent throat infection on children and their families. Fam Pract 19: 242-246, 2002. (Pubitemid 34567647)
7. Leder K. Respiratory illness during winter: A cohort study of urban children from temperate Australia. J Paediatr Child Health 41:125-129, 2005.
8. Bellanti JA. Recurrent respiratory tract infections in paediatric patients. Drugs 54:1-4, 1997. (Pubitemid 27417390)
9. Del-Rio-Navarro BE, Espinosa R, Flenady V, and Sienra-Monge JJ. Immunostimulants for preventing respiratory tract infection in children. Cochrane Database Syst Rev 18:CD004974, 2006. (Pubitemid 46841223)
10. Van Cauwenberge P, Bordeaux G, Morineau A, et al., for the Rhinitis Survey Group. Use of Diagnostic clusters to assess the economic consequences of rhynopharyngitis in children in Italy and France during the winter. Clin Ther 21:404-421, 1999.
11. Banz K, Schwicker D, and Thomas AM. Economic evaluation of immunoprophylaxis in children with recurrent ear, nose and throat infections. Pharmacoeconomics 6:464-477, 1994.
12. Schwarz B, and Dangl-Neugaard B. An economic analysis using Ribosomal immunotherapy to treat children with recurrent upper respiratory tract infections. Clin Drug Invest 14:206-210, 1997. (Pubitemid 27437705)
13. Banz K, Thomas AM, and Olivieri D. Economic evaluation of ribosomal immunotherapy in patients with chronic ear, nose and throat and respiratory tract infections: Results for Italy. BioDrugs 10:385-396, 1998. (Pubitemid 28525335)
14. Berdeaux G, Lafuma A, Perruchet AM, et al. Cost effectiveness of immunoprophylaxis in the prevention of recurrent infectious rhinitis in adults. Pharmacoeconomics 14:313-322, 1998. (Pubitemid 28416934)